Oral PDE4B Inhibitor Gets Breakthrough Tx Status for Idiopathic Pulmonary Fibrosis
BI 1015550 is an investigational oral phosphodiesterase 4B inhibitor with combined antifibrotic and anti-inflammatory effects.
Restrictive Lung Disease
Interstitial Lung Disease Diagnosis: Safety, Utility of Surgical Lung Biopsy
Surgical lung biopsies that are performed via video-assisted thoracic surgery are safe for obtaining histopathologic tissue for select patients.
Early Initiation of Tocilizumab May Preserve Lung Function in SSc-ILD
Early identification if interstitial lung disease (ILD), followed by subsequent tocilizumab therapy initiation, may preserve lung function in patients with systemic sclerosis-associated ILD.
Trials Evaluating Ziritaxestat for Idiopathic Pulmonary Fibrosis Discontinued
Ziritaxestat is an investigational autotaxin inhibitor.
Pirfenidone Gets Priority Review for Unclassifiable Interstitial Lung Disease
The sNDA includes data from a phase 2 trial that evaluated the efficacy and safety of pirfenidone in patients with progressive fibrosing UILD.
Increased GERD Risk in End-Stage Lung Disease Without Esophageal Disease
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Nintedanib Slows Rate of FVC Decline in Fibrosing Interstitial Lung Diseases
Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
Malignancies May Occur Earlier in Men vs Women After Sarcoidosis Diagnosis
In patients with sarcoidosis, cancer was found to develop earlier in men vs women.
Comparing Mortality Risks Between Idiopathic Pulmonary Fibrosis Treatments
In patients with idiopathic pulmonary fibrosis, treatment with pirfenidone was associated with a lower risk of mortality and acute respiratory-related hospitalizations than treatment with nintedanib.
Perceptions, Practices in RA-ILD Differ Between Rheumatologists and Pulmonologists
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
